Interesting novel approaches include the addition of denosumab, a monoclonal antibody targeting the RANK-ligand RANKL, to neoadjuvant chemotherapy in unselected breast cancer patients as RANKL apparently plays a key role in breast carcinogenesis (GeparX; EudraCT No.: 2015-001755-72) [29]. The gene discussed is TNFSF11; the disease is breast cancer.